Exhibit 99.9
Town Hall talking points
• | As many if not all of you may have noticed, today we announced that we have entered into an acquisition agreement with Merck |
• | Today’s news is an outstanding reason to celebrate |
• | This engagement with a preeminent, global pharma company is a great success for the team and a testament to everyone’s exceptional work and the drug programs you’ve helped to create |
• | Pandion is an attractive company for all the reasons you know, namely our... |
• | People |
• | Culture |
• | Quality of our work |
• | Science |
• | Innovation |
• | Great clinical data |
• | Merck has the expertise and resources available to fully realize the value of our programs |
• | Global clinical development |
• | Infrastructure to support large indications |
• | Salesforce around the world |
• | Financial resources |
• | Building out protein development capabilities |
• | In summary, Merck can develop our programs all the way to patients across many indications, and the Board believed this would maximize the potential for our programs and the TALON platform |
• | Specifically, PT101 is poised to enter patient clinical trials and there are many autoimmune diseases outside of UC and SLE for which Merck can rapidly expand the clinical development of PT101 |
• | Many of the details of the transaction are still being worked out with Merck, but we are committed to being open and transparent throughout the process |
• | This includes topics like what happens to Pandion and our team |
• | We have been assured that Merck will use its resources available to make any transition go as smoothly as it can |
• | Your managers will be scheduling small group meetings and 1x1s |
• | Questions should go to Tony or other members of the senior management team |
• | We will be partnering with Merck in the next couple of weeks to get to know them as a company |
• | We acknowledge there are lots of unanswered questions for all of us, but we want to be as transparent as possible and will communicate with you frequently |
• | For now, it is business as usual and we should continue to drive our programs forward without hesitation or delay |
• | For the next several days, we are in a very restricted period in terms of our communications |
• | You should not have any written conversations about this transaction unless directed by a member of senior management |
• | Includes: emails, social media, chats on Teams |
• | If any questions come to you from external parties regarding the transaction, do not respond and please forward them to Vikas or Michelle |
• | Thank you for everything you have done to bring Pandion to this place. It is a testament to everyone’s exceptional work and the drug programs you’ve helped to create for patients. |
• | REVIEW FAQ [filed as Ex. 99.10] |